Sector News

Rare disease specialist Spectrum eyes potential $2B-plus sale: Bloomberg

June 27, 2018
Life sciences

Biopharma M&A has picked up this year with deals dominated by rare diseases and cancer, more than $34 billion all told, not counting Takeda’s hefty $62 billion offer for Shire. Now, the much smaller Spectrum Pharmaceuticals—itself a rare disease and cancer specialist—is testing the waters for a potential sale, according to Bloomberg.

Citing people familiar with the process, the news service reports that Spectrum is working with Jefferies to explore a deal. As Bloomberg notes, the company could decide against selling.

Spectrum’s shares have been on a roll in recent years, growing from a low point of $3.52 in late 2016 to more than $20 at Tuesday’s close, after the deal news hit. The company’s market value has grown to more than $2 billion along the way. Last year, Spectrum generated $116.2 million in sales, and it’s predicting between $95 million and $115 million in 2018 sales.

Spectrum markets six oncology and hematology products, including one that Reinsurance Group of America profiled last year as one of the world’s priciest medications. Foloytn, according to the group, carries a list price of about $450,000 annually to treat peripheral T-cell lymphoma.

Other meds in the company’s portfolio include Zevalin for certain non-Hodgkin’s lymphoma patients and Marqibo to treat certain patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.

It’s also seeking to expand its offerings, including with poziotinib, an HER inhibitor under phase 2 testing in several cancers that Spectrum licensed in 2015 from South Korea-based Hanmi Pharmaceuticals. It’s seeking a breakthrough designation from the FDA for that drug and aiming for patent protection out to 2037, execs said on a conference call last month.

After notably slow M&A in recent years, some industry watchers have predicted dealmaking would pick up in 2018 after the U.S. government passed tax reform. Sure enough, Sanofi nabbed Bioverativ and Ablynx in January in deals worth $11.6 billion and $4.8 billion, respectively.

The same month, Celgene bought CAR-T player Juno Therapeutics for $9 billion, and Novartis in April scooped up AveXis for $8.7 billion. Takeda in May followed those buyouts with the biggest biopharma deal in recent years, a $62 billion offer for Shire.

Recent success in gene therapy will likely trigger more M&A this year as global biopharmas continue seek growth, market watchers recently predicted in Forbes. Last year, Gilead Sciences bought Kite Pharma for $11.9 billion to get a foothold in the promising CAR-T field.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).